BridgeBio issues $632.5 million convertible notes due 2033

BridgeBio Pharma Inc. (NASDAQ: BBIO) issued $632.5 million in convertible senior notes due 2033 through a private offering to qualified institutional buyers on January 21, 2026, according to a company statement.

The notes carry a 0.75% annual interest rate and mature on February 1, 2033. Interest payments occur semiannually on February 1 and August 1, beginning August 1, 2026. The offering included an additional $82.5 million from initial purchasers exercising their option to buy more notes.

BridgeBio received approximately $619.3 million in net proceeds after deducting underwriter discounts and estimated offering expenses. The company plans to use proceeds to repurchase, settle conversion obligations or repay a portion of its existing 2.50% convertible senior notes due 2027, plus general corporate purposes including working capital and capital expenditures.

The notes are convertible into cash, common stock or a combination at BridgeBio's discretion. The initial conversion rate is 9.0435 shares per $1,000 principal amount, equivalent to a conversion price of approximately $110.58 per share.

Holders may convert notes before November 1, 2032 under specific conditions, including when the stock price reaches at least 130% of the conversion price for 20 trading days in a 30-day period during certain calendar quarters. After November 1, 2032, holders may convert at any time until maturity.

BridgeBio also intends to use $82.5 million of existing cash to repurchase 1,081,825 common shares from certain note purchasers in private transactions. U.S. Bank Trust Company serves as trustee for the notes.

You May Also Be Interested In